

## Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob and Maculia

### Cambridge is a strategic position for development, regulatory

**Cambridge (Mass), November 17, 2015** – Biophytis SA (Alternext Paris: ALBPS), an emerging geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), today announced the creation of Biophytis Inc, a new subsidiary in Cambridge, Massachusetts. The early opening, initially planned for the first half of 2016, will facilitate clinical development of the companies mid-stage clinical development program, Sarcob to treat sarcopenic obesity and Maculia to treat dry AMD.

Stanislas Veillet, CEO of Biophytis said, *"we are thrilled to establish our U.S. headquarters in Cambridge, the international capital of our industry. This strategic position, opening ahead of schedule, strengthens our ability to attract the best staff and execute on our clinical development plans and partnering goals."*

Sarcob are orally available selective MAS receptor agonists, which have demonstrated preclinical proof of concept for sarcopenic obesity and satisfactory safety and tolerability in clinical Phase I testing. The the lead drug-candidate in the Sarcob program, BIO 101, is scheduled to enter Phase IIb clinical trials in mid-2016. To learn more, please visit: <http://www.biophytis.com/en/pipeline/plateforme-sarcob/>

Maculia are orally available subtype selective PPAR alpha agonists, which have demonstrated preclinical proof concept for age related macular degeneration and satisfactory safety and tolerability in Phase I testing. The lead drug-candidate in the Maculia program, BIO 201, is expected to enter Phase IIb clinical trials in mid-2016. To learn more, please visit: <http://www.biophytis.com/en/pipeline/plateforme-maculia/>

Located in the nerve center of the biotech industry, Biophytis Inc will hire U.S. staff for clinical development and use the new site to strengthen its U.S. network of key opinion leaders and improve business development relationships with leading pharmaceutical and biotechnology companies, as well as the U.S. regulatory authorities and institutional investors

**Biophytis SA** ([www.biophytis.com](http://www.biophytis.com)) discovers and develops drug candidates targeting diseases of aging. Using its proprietary plant-derived chemical library, screening technology and know-how, Biophytis has discovered multiple agents that may interfere with degenerative processes associated with aging. The Company is preparing Phase IIb clinical development of the first of these drug-candidates, Sarcob to restore the muscular function and Maculia, to restore visual function in sarcopenic obesity and dry AMD, both diseases with significant unmet medical need.

Biophytis is headquartered in Paris, France. The company was founded in 2006 by researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at ICAN (Institute of Cardiometabolism and Nutrition), the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime



**Contacts:**

**BIOPHYTIS**

**Stanislas Veillet**

Chief Executive Officer  
contact@biophytis.com  
Tel : +33 (0) 1 41 83 66 00

**Press & Investors relations  
Milestones**

**Bruno Arabian**

barabian@milestones.fr  
Tel : +33 (0) 1 83 62 34 84  
Mob : +33 (0) 6 87 88 47 26

**LifeSci Advisors**

**Chris Maggos**

Managing Director, Europe  
chris@lifesciadvisors.com  
Tel : +41 79 367 6254